Open Payments

St. Vincent Hospital

Type
Teaching hospital
Where
Santa Fe, NM
Medicare CCN
320002
Received
$275,253 in 34 records, 2025 ($47,094 general, $228,159 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment17$47,094
2025Research payment17$228,159

By company

CompanyRecordsAmountYears
Coherus Oncology, Inc.4$72,5252025
AstraZeneca UK Limited1$71,7502025
Janssen Research & Development, LLC8$58,2892025
PFIZER INC.8$27,8662025
AstraZeneca Pharmaceuticals LP3$22,7272025
PROGENICS PHARMACEUTICALS, INC.1$5,1752025
ARRAY BIOPHARMA INC1$5,0002025
Bayer Healthcare Pharmaceuticals Inc.1$5,0002025
Stryker Corporation3$4,6392025
Insulet Corporation3$2,2502025
Bio-Rad Laboratories, Inc.1$302025

By nature of payment

NatureRecordsAmount
Research payment17$228,159
Compensation for services other than consulting, including serving as faculty or as a speaker at a v9$22,250
Space rental or facility fees (teaching hospital only)4$20,175
Long term medical supply or device loan3$4,639
Debt forgiveness1$30

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Stryker Corporation$1,935Long term medical supply or device loanIn-kind items and servicesPRIME SERIES Device, PATIENT HANDLING - PH2025
2025-12-31Stryker Corporation$1,935Long term medical supply or device loanIn-kind items and servicesPRIME SERIES Device, PATIENT HANDLING - PH2025
2025-12-31Stryker Corporation$769Long term medical supply or device loanIn-kind items and servicesConnected OR Hub Device, ENDOSCOPY2025
2025-12-30Janssen Research & Development, LLC$780Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Rea2025
2025-12-30Janssen Research & Development, LLC$390Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Rea2025
2025-12-26Janssen Research & Development, LLC$16,333Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Dar2025
2025-12-08PFIZER INC.$680Research paymentIn-kind items and servicesA RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE PF08046054SGNPDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUS2025
2025-12-08PFIZER INC.$680Research paymentIn-kind items and servicesA RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE PF08046054SGNPDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUS2025
2025-12-02Bio-Rad Laboratories, Inc.$30Debt forgivenessCash or cash equivalentBiotestcell 1 & 2 Device, Antiglobulin test2025
2025-11-26Janssen Research & Development, LLC$1,560Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Rea2025
2025-11-19Insulet Corporation$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-11-10Janssen Research & Development, LLC$134Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Rea2025
2025-11-06Coherus Oncology, Inc.$20,137Research paymentCash or cash equivalentCHS388022025
2025-11-03Janssen Research & Development, LLC$7,416Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Dar2025
2025-10-10Coherus Oncology, Inc.$21,060Research paymentCash or cash equivalentCHS114022025
2025-09-19PFIZER INC.$11,506Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC C2025
2025-09-10AstraZeneca Pharmaceuticals LP$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-09-10AstraZeneca Pharmaceuticals LP$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentLYNPARZA Drug, Oncology2025
2025-09-08PROGENICS PHARMACEUTICALS, INC.$5,175Space rental or facility fees (teaching hospital only)Cash or cash equivalentPYLARIFY Drug, RADIOPHARMACEUTICAL2025
2025-08-29ARRAY BIOPHARMA INC$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentXTANDI Drug, ONCOLOGY2025
2025-08-29PFIZER INC.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentXTANDI Drug, ONCOLOGY2025
2025-08-29PFIZER INC.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentXTANDI Drug, ONCOLOGY2025
2025-08-29PFIZER INC.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentXTANDI Drug, ONCOLOGY2025
2025-08-29PFIZER INC.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentXTANDI Drug, ONCOLOGY2025
2025-08-29PFIZER INC.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentXTANDI Drug, ONCOLOGY2025
2025-08-01Bayer Healthcare Pharmaceuticals Inc.$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentXofigo Drug, Oncology2025
2025-07-31Coherus Oncology, Inc.$10,477Research paymentCash or cash equivalentCHS388022025
2025-06-26Coherus Oncology, Inc.$20,850Research paymentCash or cash equivalentCHS388022025
2025-06-12Janssen Research & Development, LLC$30,375Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Dar2025
2025-06-12Janssen Research & Development, LLC$1,300Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Dar2025
2025-03-05Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-03-03Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-02-14AstraZeneca UK Limited$71,750Research paymentCash or cash equivalentCAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestra2025
2025-01-15AstraZeneca Pharmaceuticals LP$12,727Research paymentCash or cash equivalentIMFINZI Biological, OncologyA Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination with Tremelimumab Lenv2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Santa Fe CountySanta Fe city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Santa Fe, NM, county Santa Fe County, NM, state New Mexico; placed by its city name.

MeasurePlace (city or town)
Santa Fe, NM
County
Santa Fe County, NM
State
New Mexico
Population B0100389,019156,1052,120,246
Population, 2020 census P187,505154,8232,117,522
Median age B0100246.348.739.4
Under 18 B0100116.0%16.1%21.7%
65 and over B0100126.2%28.0%19.3%
Households B1100141,92170,767837,414
Foreign born B0500215.3%12.1%9.4%
Median household income B19013$73,482$79,071$64,059
Median family income B19113$89,585$97,273$79,556
Per capita income B19301$50,299$52,207$36,218
Poverty rate B1700112.9%12.0%17.8%
Unemployment rate B230255.1%5.3%6.0%
Civilian labor force B2302546,58976,615975,902
Mean commute (minutes) B0801321.023.823.5
Bachelor's degree or higher B1500347.8%46.1%31.0%
Housing units B2500146,60878,834956,964
Owner-occupied B2500363.6%71.5%70.0%
Renters B2500336.4%28.5%30.0%
Median home value B25077$444,900$446,300$248,100
Median gross rent B25064$1,463$1,389$1,067
White, not Hispanic B0300242.5%44.0%36.0%
Black B030021.1%0.8%1.8%
Hispanic or Latino B0300249.5%47.9%48.4%
Asian B030021.9%1.4%1.6%
American Indian and Alaska Native B030021.4%2.4%8.5%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Santa Fe, NM.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.